There are currently no generic forms of Lantus (insulin glargine) approved in the United States. Lantus is considered a "biologic" medication, and rules and regulations prevent manufacturers from making any generic biologics. Also, patents currently prohibit generic Lantus from being manufactured. The first patent should expire in May 2010, but it is not known when (or if) a generic version of Lantus will become available.
Generic Lantus: An OverviewLantus® (insulin glargine) is a prescription diabetes medication. It is a long-acting form of insulin approved to treat both type 1 and type 2 diabetes.
Lantus is made by sanofi-aventis. At this time, generic Lantus has not been approved in the United States.
When Will Generic Lantus Be Available?This is a difficult question to answer. There are at least two major obstacles preventing generic Lantus from becoming available. First, Lantus is considered a "biologic" medication and is, therefore, under different rules and laws than most other medications. At this point, generic biologics, including generic Lantus, are not allowed to be manufactured in the United States. Currently, legislation is under way that may change the laws concerning generic biologics (including insulin), but it is not clear when (or even if) this may happen.
Second, several unexpired patents protect the drug. The first of these patents already expired in May 2010. Other additional patents that expire at a later date may continue to protect Lantus from generic competition.